Chronic obstructive pulmonary disease (COPD) guidelines recommend both long-acting and dual bronchodilator therapy. It is unclear if there are differences in efficacy and safety.
Objective:
This meta-analysis evaluates the efficacy of dual therapy with long-acting β-agonist (LABA) + long acting muscarinic antagonist (LAMA) compared with monotherapy with LAMA for COPD.
Methods:
We searched PubMed, CINAHL, and Web of Science databases from inception through March 2020 to identify English-language, prospective randomized controlled trials (RCTs) that compared dual therapy with monotherapy in adult patients with COPD. Risk of bias was assessed using the Jadad score. Overall analysis was performed using Review Manager 5.3. Treatment effect was determined with the random-effects model using the Mantel-Haenszel method and was reported as mean difference (MD) with 95% CI.
Results:
A total of 18 RCTs were included (n = 6086; median Jadad score 5/5) that compared LAMA + LABA with LAMA. There was a greater improvement in forced expiratory volume at 1 s (FEV1) with dual therapy compared with LAMA: MD = 0.08; 95% CI = [0.05, 0.11]. There was no difference in St George Respiratory Questionnaire (SGRQ) scores between groups: OR = −0.85; 95% CI = [−1.83, 0.13]. There were no differences in overall adverse events (OR = 1.00; 95% CI = 0.92, 1.09), serious adverse events (OR = 1.01; 95% CI = 0.86, 1.18), or cardiovascular events (OR = 0.88; 95% CI = 0.58, 1.34).
Conclusion and Relevance:
Dual therapy improves FEV1 and is as safe as LAMA. Dual therapy does not improve SGRQ scores more than LAMA.
DonaldsonGCSeemungalTABhowmikAWedzichaJA.Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852. doi:10.1136/thorax.57.10.847
3.
WedzichaJADecramerMFickerJH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209. doi:10.1016/S2213-2600(13)70052-3
4.
CalverleyPMAAnzuetoARCarterK, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337-344. doi:10.1016/S2213-2600(18)30102-4
5.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi:10.1371/journal.pmed.1000097
6.
Review Manager (RevMan) [computer program]. Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
7.
JadadARMooreRACarrollD, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials. 1996;17:1-12.
8.
BorensteinMHedgesLHigginsJRothsteinH.Comprehensive Meta-Analysis Version 3. Biostat; 2013.
9.
DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchA.Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-1546. doi:10.1016/j.rmed.2013.06.001
10.
CelliBCraterGKilbrideS, et al. Once-daily umecidinium/vilanterol 125/25 mcg therapy in COPD: a randomized, controlled study. Chest. 2014;145:981-991. doi:0.1378/chest.13-1579
11.
DonohueJFNiewoehnerDBrooksJO’DellDChurchA.Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double blind, placebo-controlled study. Respir Res. 2014;15:78. doi:10.1186/1465-9921-15-78
12.
DecramerMAnzuetoAKaelinT, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicenter, blinded, randomized controlled trials. Lancet Respir Med. 2014;2:472-486. doi:10.1016/S2213-2600(14)70065-7
13.
Maleki-YazdiMRKaelinTRichardNZvarichMChurchA.Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized controlled trial. Respir Med. 2014;108:1752-1760. doi:10.1016/j.rmed.2014.10.00
14.
KerwinEMKalbergCJGalkinDV, et al. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Int J Chron Obstruct Pulmon Dis. 2017;12:745-755. doi:10.2147/COPD.S119032
15.
BatemanEDFergusonGTBarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484-1494. doi:10.1183/09031936.00200212
16.
AsaiKHirataKHashimotoS, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig. 2016;54:428-435. doi:10.1016/j.resinv.2016.06.006
17.
HashimotoSIkeuchiHMurataSKitawakiTIkedaKBanerjiD.Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study. Int J Chron Obstruct Pulmon Dis. 2016;11:2543-2551. doi:10.2147/COPD.S111408
18.
SinghDJonesPWBatemanED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-178
19.
D’UrzoARennardSKerwinE, et al. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39-48. doi:10.1016/j.rmed.2017.02.008
20.
SethiSKerwinEWatzH, et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667-682. doi:10.2147/COPD.S189138
21.
ZuWallackRAllenLHernandezGTingNAbrahamsR.Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133-1144. doi:10.2147/COPD.S72482
22.
BuhlRMagderSBothnerU, et al. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58-66. doi:10.1016/j.rmed.2016.11.011
23.
MahlerDAD’UrzoABatemanED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781-788. doi:10.1136/thoraxjnl-2011-201140
24.
JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJA.Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250-255. doi:10.1164/rccm.201310-1863PP
DonohueJFJonesPWBartelsC, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11-19. doi:10.1016/j.pupt.2017.12.005
27.
VestboJLangeP.Natural history of COPD: focusing on change in FEV1. Respirology. 2016;21:34-43. doi:10.1111/resp.12589
28.
DecramerMLChapmanKRDahlR, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1:524-533. doi:10.1016/S2213-2600(13)70158-9
29.
VogelmeierCHedererBGlaabT, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093-1103. doi:10.1056/NEJMoa1008378
30.
ObaYKeeneyEGhatehordeNDiasS.Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;(12):CD012620. doi:10.1002/14651858.CD012620.pub2
31.
GregorianoCDieterleTBreitensteinAL, et al. Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. Respir Res. 2018;19:237. doi:10.1186/s12931-018-0936-3
